Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics

VENTANA DP 600 Slide Scanner (Source: Roche Diagnostics)
  • The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment.
  • Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.1 Many cancers can be cured if detected early and treated effectively.1
  • The Roche Digital Pathology solution helps empower the digital transformation of pathology and enable better, more personalised healthcare.

Johannesburg, 31st – On August 2022 –Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the CE launch of the next-generation VENTANA DP 600 slide scanner (CE-IVD marked). This high-capacity slide scanner produces excellent image quality of stained histology slides from patient tissue samples, while providing ease-of-use and workflow flexibility for the pathology lab1.

“The VENTANA DP 600 slide scanner is vital for the advancement of healthcare in Africa. This solution helps to ensure that each patient receives the most effective treatment plan possible, regardless of where they live,” said Alan Yates Ad-Interim General Manager of Roche Diagnostics. He added, “When combined with our innovative AI image analysis algorithms, the VENTANA DP 600 creates opportunities for better collaboration and remote diagnosis, which can be lifesaving in African countries with large rural populations. Innovative solutions such as this allow us to move closer to our vision of enabling health for every African.”

The VENTANA DP 600 slide scanner is an important addition to the Roche Digital Pathology portfolio, which provides innovative, high-quality digital solutions that automate tissue diagnostics and empower pathologists to provide faster and more comprehensive diagnostic results to healthcare providers and their patients2.

Digital Pathology refers to the digitalisation of the traditional pathology workflow starting from slide scanning to visualisation to analysis. Digital Pathology is transforming traditional histopathology by improving efficiency, depth of analysis, and opportunity for collaboration in pathology workflows.

For example, once the slide scanner captures and converts stained tissue on glass slides to digital images, these images can be managed, shared, and analysed by pathologists and can help determine a cancer patient’s treatment.

This new 240-slide scanner, which builds on the success of the 6-slide VENTANA DP 200 scanner, will help anatomic pathology laboratories accelerate the digitalisation of their pathology workflow. Both scanners feature the same innovative optics and dynamic focus technology for high-resolution, high-quality colour images that accurately reproduce the image quality that pathologists see under microscopes.

About Roche Digital Pathology 

Built by pathologists, for pathologists, the end-to-end Roche Digital Pathology solution focuses on maximising the pathologists’ unique training, skills, and vision. The Roche Digital Pathology solution is an integrated solution that combines innovative slide scanners, patient-centric pathology workflow software and image analysis algorithms, working in integrated harmony with the full Roche tissue diagnostics portfolio.

The newest addition to the Roche Digital Pathology portfolio is the 240-slide, high-capacity brightfield VENTANA DP 600 slide scanner that offers workflow flexibility to suit a variety of anatomical pathology labs.

VENTANA slide scanners use tray-based systems engineered with minimal moving parts. The slides move through the system on the tray without interference by a robotic mechanism, allowing for a high-quality scan even if the slides are wet, frozen, or if cover slips are slightly off centre. The tray-based system eliminates slide-handling errors such as breakage and loss of slides2.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit

All trademarks used or mentioned in this release are protected by law. The VENTANA DP 600 slide scanner is available as Research Use Only (RUO) in the United States, not for use in diagnostic procedures. Refer to the product-specific labelling for the regulatory status of scanners and/or algorithms.


[1] WHO Cancer Facts,



Please enter your comment!
Please enter your name here